FDA Revises Paxlovid, Lagevrio EUAs Removing Positive COVID-19 Test Requirement
The FDA has revised the EUAs for Paxlovid and Lagevrio for the treatment of mild to moderate COVID-19.
Diagnosis & Disease Information
Biden to Lift COVID-19 Emergencies in May
After that, COVID-19 would be treated as an endemic threat managed by more typical public health authorities
COVID-19 Pandemic at a Tipping Point: WHO
Organization’s International Health Regulations Emergency Committee met last week to discuss COVID-19
Bivalent Vaccine Provides Added Protection Against BA.5, XBB/XBB.1.5
Additional protection against symptomatic infection provided for people who had previously received monovalent vaccine doses
FDA Revises Evusheld EUA Halting Use of the COVID-19 Therapy for Now
Recent data show that the product is unlikely to be active against currently circulating SARS-CoV-2 variants.
Uptake Low for COVID-19 Vaccine Boosters in Immunocompromised Adults
Authors found low adherence to CDC recommendations for boosters, with older adults more likely to receive at least four mRNA COVID-19 vaccine doses
No Increase Seen in OD Deaths Involving Buprenorphine During COVID-19
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
Respiratory Virus Coinfection May Up SARS-CoV-2 Severity in Children Under 5
For children younger than 5 years, having any viral codetection or rhinovirus/enterovirus codetection significantly linked to severe illness
Convalescent COVID-19 Plasma Beneficial for Immunocompromised
Reduction seen in mortality with COVID-19 convalescent plasma transfusion in randomized clinical trials, matched cohort studies
Safety Signal in Seniors Prompts Investigation of Bivalent COVID-19 Vaccine
The preliminary safety signal was identified by the CDC’s Vaccine Safety Datalink.
